Tenpoint Therapeutics launches with $70M Series A financing to reverse vision loss

Tenpoint Therapeutics is a biotechnology company that was established based on the pioneering work of its scientific founders from Moorfields Eye Hospital, University College London Institute of Ophthalmology, Institut de la Vision in Paris, and the University of Washington, who have developed engineered cell-based therapeutics and performed translational research to establish proof-of-concept. Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.